01999nas a2200217   4500000000100000000000100001008004100002260001500043653001600058653003100074653002500105653001800130653001300148100001700161700001600178245005600194856014400250490000700394520136600401022001401767       2025                            d  c2025-04-2110aapplication10ainflammatory bowel disease10aintestinal organoids10anew therapies10aprogress1 aJianzhen Ren1 aSilin Huang00aIntestinal Organoids for Inflammatory Bowel Disease  uhttps://www.frontiersin.orghttps://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2025.1517121/abstract0 v133 aInflammatory bowel disease (IBD) is a chronic relapsing-remitting immune-mediated disorder affecting the gastrointestinal tract with unknown etiology, and its incidence is on the rise worldwide. IBD is related to five major factors: genetic susceptibility, immune dysregulation, intestinal epithelial mechanical barrier damage, intestinal microbial dysbiosis, and environmental stimulation. At a molecular level, intrinsic deficiencies in epithelial integrity, mucosal barrier function, and mechanisms of immune response and resolution contribute to the development of IBD. Intestinal epithelial repair and mucosal healing are the goals of IBD treatment, and play an important role in the pathogenesis and treatment of IBD. Intestinal organoids, are three-dimensional cellular structures that recapitulate the basic architecture and functional processes of the organ of origin, retain the genetic and transcriptomic profile of the tissue of origin, and provide a good in vitro model for the study of intestinal epithelium in IBD. Recent studies have revealed that functional disruption of the intestinal epithelium is closely related to the pathogenesis of IBD, and IBD research using organoids has attracted attention. In this review, we describe the origin of intestinal organoids and summarize the application and progress of this technology in IBD research.  a2296-634X